MOZART SILVIO PEREIRA

Dr. MOZART SILVIO PEREIRA


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2026 in Biochimie
Verified
Journal Article
Closed access
JRJúlia T. Rodrigues
Júlia T. Rodrigues
MPMOZART SILVIO PEREIRA
MOZART SILVIO PEREIRA
LBLucas Bleicher
Lucas Bleicher
TBTiago A.DA S. Brandão
Tiago A.DA S. Brandão
MMMariana Torquato Quezado De Magalhaes
Mariana Torquato Quezado De Magalhaes

16 June 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
MPMOZART SILVIO PEREIRA
MOZART SILVIO PEREIRA
HAHeveline Oliveira Morais Arruda
Heveline Oliveira Morais Arruda
DMDiego Martins
Diego Martins
PFPhilipe Oliveira Fernandes
Philipe Oliveira Fernandes
ASAdriano Sabino
Adriano Sabino
AMAdolfo Henrique Moraes
Adolfo Henrique Moraes
Janus kinase 2 (JAK2) occupies a central position in cytokine signaling and plays essential roles in hematopoiesis, immune regulation, and cancer. Although recent advances in structural biology, cryo-EM, receptor modeling, and biophysical analysis have substantially expanded current views of JAK2 function, key mechanistic questions remain regarding how receptor geometry, JH2-mediated autoinhibition, and disease-associated mutations are structurally integrated. In this review, we discuss the multidomain organization of JAK2 and examine how the FERM–SH2 module, the pseudokinase domain (JH2), and the catalytic kinase domain (JH1) cooperate to govern receptor specificity, allosteric control, and cytokine-induced activation. We further analyze how pathogenic mutations rewire this regulatory system by weakening autoinhibitory contacts, altering linker-mediated communication, or stabilizing active dimeric conformations. Finally, we assess current and emerging therapeutic strategies, from ATP-competitive inhibitors to macrocyclic and JH2-selective allosteric modulators, with emphasis on how structural insight can guide next-generation drug design. These advances support a more integrated view of JAK2 regulation and define new opportunities for selective therapeutic intervention.